Literature DB >> 34602950

Expert Discussion: HER2-Positive Breast Cancer.

Theodoros Foukakis1,2, Alexios Matikas1,2, Olga Oikonomidou3, Eleni Andreopoulou4, Dimitris Mavroudis5.   

Abstract

Entities:  

Year:  2021        PMID： 34602950      PMCID： PMC8436631          DOI： 10.1159/000516965

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.268


× No keyword cloud information.
  7 in total

1.  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Sara M Tolaney; Hao Guo; Sonia Pernas; William T Barry; Deborah A Dillon; Lauren Ritterhouse; Bryan P Schneider; Fei Shen; Kit Fuhrman; Michele Baltay; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Mathew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth Overmoyer; Ann H Partridge; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

2.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

3.  PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors:  S Loibl; I Majewski; V Guarneri; V Nekljudova; E Holmes; E Bria; C Denkert; C Schem; C Sotiriou; S Loi; M Untch; P Conte; R Bernards; M Piccart; G von Minckwitz; J Baselga
Journal:  Ann Oncol       Date:  2016-05-13       Impact factor: 32.976

4.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

5.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

6.  A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.

Authors:  Aleix Prat; Valentina Guarneri; Laia Paré; Gaia Griguolo; Tomás Pascual; Maria V Dieci; Núria Chic; Blanca González-Farré; Antonio Frassoldati; Esther Sanfeliu; Juan M Cejalvo; Montserrat Muñoz; Giancarlo Bisagni; Fara Brasó-Maristany; Loredana Urso; Maria Vidal; Alba A Brandes; Barbara Adamo; Antonino Musolino; Federica Miglietta; Benedetta Conte; Mafalda Oliveira; Cristina Saura; Sònia Pernas; Jesús Alarcón; Antonio Llombart-Cussac; Javier Cortés; Luis Manso; Rafael López; Eva Ciruelos; Francesco Schettini; Patricia Villagrasa; Lisa A Carey; Charles M Perou; Federico Piacentini; Roberto D'Amico; Enrico Tagliafico; Joel S Parker; Pierfranco Conte
Journal:  Lancet Oncol       Date:  2020-11       Impact factor: 41.316

7.  HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Authors:  David M Hyman; Sarina A Piha-Paul; Helen Won; Jordi Rodon; Cristina Saura; Geoffrey I Shapiro; Dejan Juric; David I Quinn; Victor Moreno; Bernard Doger; Ingrid A Mayer; Valentina Boni; Emiliano Calvo; Sherene Loi; Albert C Lockhart; Joseph P Erinjeri; Maurizio Scaltriti; Gary A Ulaner; Juber Patel; Jiabin Tang; Hannah Beer; S Duygu Selcuklu; Aphrothiti J Hanrahan; Nancy Bouvier; Myra Melcer; Rajmohan Murali; Alison M Schram; Lillian M Smyth; Komal Jhaveri; Bob T Li; Alexander Drilon; James J Harding; Gopa Iyer; Barry S Taylor; Michael F Berger; Richard E Cutler; Feng Xu; Anna Butturini; Lisa D Eli; Grace Mann; Cynthia Farrell; Alshad S Lalani; Richard P Bryce; Carlos L Arteaga; Funda Meric-Bernstam; José Baselga; David B Solit
Journal:  Nature       Date:  2018-01-31       Impact factor: 49.962
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.